Nov 3 2012
BiOptix today announced that it would be highlighting the new BiOptix 404pi, the first commercially available SPR instrument to incorporate phase-based common path interferometry technology, at the Label Free Technologies Show in Amsterdam from November 1 - 3 as well as at the PEGS Europe Summit on November 6 – 8.
"At the Label Free and PEGS Europe meetings, BiOptix will unveil new application data that demonstrates the value proposition of the upcoming BiOptix 404pi," noted Ken Wilczek, Vice President of Sales & Marketing for BiOptix. "We are excited to demonstrate how BiOptix Enhanced or Phase-based SPR differs from standard surface plasmon resonance detection methods in that BiOptix technology combines the high sensitivity of SPR with the high stability and lower noise of common path interferometry—utilizing an internal reference for increased sensitivity."
BiOptix technology allows for the simultaneous monitoring of multiple analytes in a single sample. This new class of SPR instrumentation from BiOptix has been designed to measure protein/protein and protein-small molecule interactions (down to 100 Da) in a high-throughput 96/384 well platform utilizing 4 parallel channels rather than a single flow cell.
Surface Plasmon Resonance is an advanced and highly sensitive optical technology that can measure refractive index changes on a sensor chip's gold surface due to a change in mass that occurs during a binding event. This change can be used to monitor biological interactions such as the concentration of target molecules, kinetic rates and affinity constants. BiOptix has developed and patented a novel ultra-sensitive detection platform known as Enhanced Surface Plasmon resonance, or ESPR. Unlike traditional SPR, ESPR instrumentation from BiOptix enables the high sensitivity of SPR with the high stability and lower noise of common path interferometry.
Source: http://www.bioptixanalytical.com/